News Releases / 2016
CMH Treats First Patients in Ventura with Minimally Invasive UroLift® System for Enlarged Prostate
Ventura, California, 09/02/2016
Condition Impacts One in Four Men by Age 55
Community Memorial Hospital today announced that their first patients have been treated with the UroLift® System, an innovative new treatment for benign prostatic hyperplasia (BPH), also known as enlarged prostate.
The UroLift System is designed to relieve symptoms caused by an enlarged prostate, while preserving sexual function. Delivered during a minimally invasive procedure, the UroLift permanent implants act like window curtain tie-backs to hold the lobes of an enlarged prostate open. Patients recover from the procedure quickly and return to their normal routines with minimal downtime. The cost of the UroLift System procedure is covered by Medicare in California.
“I see many patients whose lives are negatively impacted by symptoms related to their enlarged prostate, but they are concerned about treatment because many patients are concerned about side effects,” said Dr. Marc Beaghler, a urologist at Community Memorial Hospital in Ventura, who performed the first procedures. “The UroLift System has an excellent safety profile and provides men suffering from an enlarged prostate a beneficial first-line treatment alternative to drug therapy or more invasive surgery. Importantly, the UroLift System provides fast and meaningful relief from BPH symptoms, improving overall quality of life for our patients.”
Benign prostatic hyperplasia affects more than 37 million men in the United States alone. Twelve times more common than prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Approximately one in four men experience BPH-related symptoms by age 55, with 90 percent of men over 70 symptomatic.
Data from clinical trials showed that patients receiving UroLift implants reported rapid symptomatic improvement, improved urinary flow rates, and sustained sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure.
About BPH Treatment
More than 500 million aging men worldwide have an enlarged prostate. Medication is often the first line therapy but relief can be inadequate and temporary. Side effects of treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts or ablates prostate tissue to open the blocked urethra. While current surgical options, such as the 'gold standard' surgery, Transurethral Resection of the Prostate (TURP), can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation (dry orgasm).
The UroLift System provides an alternative to tissue removing surgery for the treatment of an enlarged prostate. Performed through the urethra, a urologist uses the UroLift System to push aside the obstructive prostate lobes and positions small, tailored permanent UroLift implants to hold the prostate lobes in the retracted position. This opens the urethra while leaving the prostate intact. Adverse reactions associated with UroLift System treatment were comparable to other minimally invasive surgical therapies as well as standard cystoscopy. The most common adverse events reported during the study included pain or burning with urination, blood in the urine, pelvic pain, urgent need to urinate, and the inability to control urine because of an urgent need to urinate. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. For more information about UroLift, visit www.urolift.com.